Compare AbbVie Inc (ABBV) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Global X Uranium ETF — how do they compare? AbbVie Inc trades at $248.3 (market cap $441.94B), while Global X Uranium ETF trades at $45.4. The key difference: AbbVie Inc pays a 2.77% dividend while Global X Uranium ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | URA | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $263.58 | $61.81 |
52-Week Low | $197.38 | $36.45 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
URA, the Global X Uranium ETF, trades at $45.34, up 2.16% today with a bullish technical signal from moving averages. The ETF benefits from strong nuclear energy tailwinds including $17.5 billion in federal funding and growing AI power demand. Recent index additions like Terra Innovatum and Eagle Nuclear Energy expand the fund's exposure to nuclear infrastructure companies.
The uranium sector faces near-term volatility but long-term structural growth drivers remain intact. Key risks include policy uncertainty and uranium price fluctuations, while opportunities stem from nuclear energy's role in meeting AI power demands and global decarbonization goals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
